Vivos Therapeutics opened lower at $0.09, compared with its previous close of $0.09. In the last trading session, the stock traded between $0.09 and $0.09. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Vivos Therapeutics is now worth
$ 0.10
Resulting in a loss of
$ 99.90 (99.90%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+$0.00 (+4.42%)
Day High
$0.09
Day Low
$0.09
Day Open
$0.09
Prev Close
$0.09
Volume
4,60,045
1W Return
-15.63%
1M Return
-32.98%
3M Return
-69.22%
6M Return
-86.36%
1Y Return
-96.35%
Market Cap ($ Mn)
3
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-590.18%
ROCE
-171.83%
EPS (TTM)
$-0.41
1 Week
-15.63%
1 Month
-32.98%
3 Months
-69.22%
6 Months
-86.36%
9 Months
-94.34%
Vivos Therapeutics closes SOD deal to boost equity
Vivos Therapeutics closed acquisition of 11% equity in SOD Sciences. Issued $12 million in Series C preferred stock with no cash exchange. Deal aims to boost stockholders' equity above Nasdaq minimums. Access to 325,000 patients via American Health Associates partnership.
24 days agoVivos Therapeutics targets $3.6M annual cost savings from Q4 2026
Vivos Therapeutics targets $3.6 million in annual cost savings starting Q4 2026. Referrals at Las Vegas centers rose approximately 3-fold between June and September. EEG diagnostic testing projected to reach $1.5 million to $3.0 million annualized run rate. Payer contract renegotiations expected to add $2.4 million to $5.6 million in revenue. Management projects cash flow positivity by late 2026 or early 2027.
1mo agoVivos Therapeutics swaps $2.86 million debt for equity shares
Vivos Therapeutics exchanged $2,861,270 of Streeterville Note principal for 11,445,080 common shares. The exchange price was set at $0.25 per share on August 31, 2026. Outstanding balance of the note stands at approximately $3.7 million as of August 31, 2026. Original principal amount was $8,225,000 recorded on June 9, 2025.
2mo agoVivos Therapeutics signs South Florida sleep center deal
Vivos Therapeutics signs deal with South Palm Cardiovascular Associates for Florida sleep center. AIM Florida LLC will be formed with Vivos holding a 75% majority interest. Center targets ~250 monthly patients and up to $6 million annual revenue. Contribution margins projected at 30% or more once fully deployed. Revenue generation expected to begin in Q1 2027.
2mo agoVivos Therapeutics sees 212% rise in Nevada sleep apnea referrals
New OSA patient referrals rose 212% in the last six weeks. Average weekly referrals have grown nearly five-fold since June 1. New 8,100 sq. ft. Henderson facility aims for $10 million annual capacity. Company targets 200,000 undiagnosed Nevadans with sleep apnea.
2mo agoVivos Inc. starts IsoPet shipments from US facility; secures India regulatory nod
Vivos Inc. has commenced IsoPet shipments from its new U.S. facility in Washington state, eliminating reliance on third-party manufacturers. Concurrently, the company secured authorization from India’s AERB to establish an international manufacturing center, creating a dual-site global production structure. These moves support both its commercial veterinary program, which serves 17 clinics, and its clinical human therapy pipeline.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Vivos Therapeutics is now worth
$ 0.10
Resulting in a loss of
$ 99.90 (99.90%)
Note: Past profits do not guarantee future returns.
